Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23837276 | 1.00 | ADORA2A (0.56) | ADORA2AADORA1ADORA3GSK3AGSK3B | |
| SCHEMBL21628114 | 1.00 | ADORA2A (0.56) | ADORA2AADORA1ADORA3GSK3AGSK3B | |
| SCHEMBL1847597 | 1.00 | ADORA2A (0.56) | ADORA2AADORA1ADORA3GSK3AGSK3B | |
| SCHEMBL23839858 | 1.00 | ADORA2A (0.56) | ADORA2AADORA1ADORA3GSK3AGSK3B | |
| SCHEMBL1848773 | 1.00 | ADORA2A (0.56) | ADORA2AADORA1ADORA3GSK3AGSK3B | |
| SCHEMBL21628127 | 0.99 | ADORA2A (0.55) | ADORA2AADORA1ADORA3GSK3AGSK3B | |
| SCHEMBL21628131 | 0.99 | ADORA2A (0.55) | ADORA2AADORA1ADORA3GSK3AGSK3B | |
| SCHEMBL1850864 | 0.97 | ADORA2A (0.53) | ADORA2AADORA1ADORA3GSK3AGSK3B | |
| SCHEMBL1848341 | 0.97 | ADORA2A (0.53) | ADORA2AADORA1ADORA3GSK3AGSK3B | |
| SCHEMBL1848345 | 0.97 | ADORA2A (0.53) | ADORA2AADORA1ADORA3GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384754-B2 | Cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | PALOBIOFARMA, S.L. (ES) | 2025-08-12 | — | — | US | claimed |
| CN-115298169-B | Co-crystals of (1R, 3S) -3- (5-cyano-4-phenyl-1, 3-thiazol-2-ylcarbamoyl) cyclopentanecarboxylic acid | 帕罗生物制药有限公司 | 2024-11-19 | — | — | CN | claimed |
| EP-4121419-B1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA SL (ES) | 2024-08-14 | — | — | EP | claimed |
| US-20230183195-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA, S.L. (ES) | 2023-06-15 | — | — | US | claimed |
| EP-4121419-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCABAMOYL)CYCLOPENTANE CARBOXYLIC ACID | Palobiofarma, S.L. (ES) | 2023-01-25 | — | — | EP | claimed |
| CN-115298169-A | Cocrystals of (1R, 3S) -3- (5-cyano-4-phenyl-1, 3-thiazol-2-ylcarbamoyl) cyclopentanecarboxylic acid | 帕罗生物制药有限公司 | 2022-11-04 | — | — | CN | claimed |
| WO-2021185748-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCABAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA, S.L. (ES) | 2021-09-23 | — | — | WO | claimed |
| EP-3882240-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCABAMOYL)CYCLOPENTANE CARBOXYLIC ACID | Palobiofarma, S.L. (ES) | 2021-09-22 | — | — | EP | claimed |
| EP-3592734-B1 | AMINE SALT OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA SL (ES) | 2021-05-19 | — | — | EP | claimed |
| US-10583127-B2 | Amine salt of (1R, 3S)-3-(5-cyano-4-phenyl-1,3- thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | PALOBIOFARMA, S.L. (ES) | 2020-03-10 | — | — | US | claimed |
| US-20200030300-A1 | AMINE SALT OF (1R, 3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA, S.L. (ES) | 2020-01-30 | — | — | US | claimed |
| US-8410282-B2 | Compounds as adenosine A1 receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2013-04-02 | — | — | US | claimed |
| EP-2197860-B1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2011-05-25 | — | — | EP | claimed |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2010-12-09 | — | — | US | claimed |
| US-12384754-B2 | Cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | PALOBIOFARMA, S.L. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-12384754-B2 | Cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | PALOBIOFARMA, S.L. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-12384754-B2 | Cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | PALOBIOFARMA, S.L. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2010-12-09 | — | — | US | disclosed |
| EP-2197860-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | Palobiofarma, S.L. (ES) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009044250-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10583127-B2 | Amine salt of (1R, 3S)-3-(5-cyano-4-phenyl-1,3- thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885 |
| US-20230183195-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885 |
| US-20200030300-A1 | AMINE SALT OF (1R, 3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885 |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885 |
| US-12384754-B2 | Cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.